ClinicalTrials.gg
CompletedNCT00933283Updated Dec 3, 2012

A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State

A Phase 1 interventional study of Telaprevir and Methadone in Healthy Participants, sponsored by Tibotec BVBA. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-03.

Sponsored by Tibotec BVBA (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of steady-state (constant concentration of medication in the blood) telaprevir 750 mg every 8 hours on the steady-state pharmacokinetics (how the drug concentrations change over time) of R- and S-methadone.

Read the detailed description

This is a Phase 1, open-label (all people know the identity of the intervention), single-sequence study to evaluate the potential interaction of steady-state telaprevir on the steady-state pharmacokinetics of methadone. The study consists of 3 phases: the screening phase (within 21 days prior to the start of supervised methadone intake on Day -14), treatment phase, and follow-up phase. Participants on stable methadone maintenance therapy will be enrolled in this study and their methadone doses will not be changed starting at Day -14. During the treatment phase, telaprevir will be added for 7 days (from Day 1 to Day 7) to participants' current methadone therapy. The methadone dosage will not to be changed from Day -14 until Day 7. All the intakes of methadone and telaprevir will be supervised and pharmacokinetic parameters will be measured during the study. Safety evaluations for adverse events, clinical laboratory tests, alcohol breath test, cardiovascular safety, and other evaluations (physical examination, and pharmacodynamic assessments) will be performed throughout the study. The total duration of the study for each participant is approximately 60 days.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy participants
  • Pharmacokinetics
  • Pharmacodynamic
  • Potential interaction
  • VX-950-TiDP24-C135
  • VX-950
  • Methadone
  • Telaprevir
  • Steady-state
03

In context

Lead sponsor

Tibotec BVBA is the lead sponsor of 18 studies on the registry; none are open to participants now.

First submitted after Tibotec BVBA became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must receive once daily oral methadone maintenance therapy at a stable individualized dose of 30 to 130 mg for at least 2 weeks prior to screening, formulated as commercially available tablets or solution
  • Must agree not to change the current methadone dose from screening until Day 7 included to have a daily observed and documented methadone intake from Day -14 until Day 8 and a daily observed and documented telaprevir intake from Day 1 until Day 7
  • Participants have to obtain approval for participation from his/her addiction physician, and the addiction physician has to agree to provide medical care for the participant after discharge from study center
  • General medical condition must not interfere with the assessments and the completion of the study
  • Health assessments will be done on the basis of physical examination, medical history, , vital signs and the results of blood biochemistry, blood coagulation and hematology tests and a urinalysis carried out at screening

Exclusion criteria

Exclusion Criteria:

  • History of any illness that could confound the results of the study or pose an additional risk in administering study medication to the participant, for eg, history of relevant medication or food allergies, history of cardiovascular or central nervous system disease, history or presence of pathology or history of mental disease
  • Consumption of herbal medications or dietary supplements, vitamins, and grapefruit or grapefruit juice, apple juice or orange juice within 14 days before Day -1
  • Current alcohol use, which, in the assessment of the investigator, could compromise participant's safety or compliance with the study protocol procedures
  • Test positive for drugs of abuse such as cocaine, amphetamines, barbiturates, benzodiazepines, or opiates on Day -2 unless explained by allowed concomitant medications
  • Participation in a clinical study involving administration of an medication within 60 days or 5 half-lives (whichever was longer) prior to the screening visit
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Telaprevir + Methadone

    Patients will receive telaprevir 750 mg orally, every 8 hours from Day 1 to Day 7, along with methadone 30 to 130 mg, once daily.

    Drug: Telaprevir · Drug: Methadone

Interventions

  • Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.

  • Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of telaprevir

    Pharmacokinetic parameter Cmax of telaprevir is measured when telaprevir will be administered at 750 mg every 8 hours for 7 days added to stable methadone maintenance therapy.

    Time frame: On Day 7

  2. Minimum plasma concentration (Cmin) of telaprevir

    Pharmacokinetic parameter Cmin of telaprevir is measured when telaprevir will be administered every 8 hours for 7 days added to stable methadone maintenance therapy.

    Time frame: On Day 7

  3. Area under the plasma concentration-time curve (AUC) of telaprevir

    Pharmacokinetic parameter AUC of telaprevir is measured when telaprevir will be administered every 8 hours for 7 days added to stable methadone maintenance therapy.

    Time frame: On Day 7

  4. Cmax of R-methadone

    Pharmacokinetic parameter Cmax of R-methadone is measured during stable methadone maintenance therapy alone and in the presence of steady-state telaprevir at 750 mg every 8 hours.

    Time frame: Day -1 and Day 7

  5. Cmin of R-methadone

    Pharmacokinetic parameter Cmin of R-methadone is measured during stable methadone maintenance therapy alone and in the presence of steady-state telaprevir every 8 hours.

    Time frame: Day -1 and Day 7

  6. AUC of R-methadone

    Pharmacokinetic parameter AUC of R-methadone is measured during stable methadone maintenance therapy alone and in the presence of steady-state telaprevir every 8 hours.

    Time frame: Day -1 and Day 7

  7. Cmax of S-methadone

    Pharmacokinetic parameter Cmax of S-methadone is measured during stable methadone maintenance therapy alone and in the presence of steady-state telaprevir at 750 mg every 8 hours.

    Time frame: Day -1 and Day 7

  8. Cmin of S-methadone

    Pharmacokinetic parameter Cmin of S-methadone is measured during stable methadone maintenance therapy alone and in the presence of steady-state telaprevir every 8 hours.

    Time frame: Day -1 and Day 7

  9. AUC of S-methadone

    Pharmacokinetic parameter AUC of S-methadone is measured during stable methadone maintenance therapy alone and in the presence of steady-state telaprevir every 8 hours.

    Time frame: Day -1 and Day 7

Secondary outcomes

  1. Short Opiate Withdrawal Scale [SOWS]

    Pharmacodynamic assessments of methadone withdrawal are performed by means of SOWS.

    Time frame: Day -7, and Day -2 to Day 7

  2. Desires for Drugs Questionnaire [DDQ]

    Pharmacodynamic assessments of methadone withdrawal are performed by means of DDQ.

    Time frame: Day -7, and Day -2 to Day 7

  3. Pupillometry

    Pharmacodynamic assessments of methadone withdrawal are performed by means of pupillometry.

    Time frame: Day -1, Day 2, Day 4, and Day 7

  4. Number of participants with adverse events

    Time frame: Up to 60 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • van Heeswijk R, Verboven P, Vandevoorde A, Vinck P, Snoeys J, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Witek J, Garg V. Pharmacokinetic interaction between telaprevir and methadone. Antimicrob Agents Chemother. 2013 May;57(5):2304-9. doi: 10.1128/AAC.02262-12. Epub 2013 Mar 11. PubMed 23478952 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Nov 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2009
First posted
Jul 7, 2009
Start
Jul 2009
Primary completionActual
Nov 2009
CompletionActual
Dec 2009
Last update
Dec 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00933283
Lead sponsor
Tibotec BVBA
Responsible party
Sponsor
First posted
Jul 7, 2009
Start date
Jul 2009
Primary completion
Nov 2009
Completion
Dec 2009
Last update
Dec 3, 2012

Study contacts

Tibotec-Virco Virology BVBA Clinical Trial
study director · Tibotec BVBA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Methadone

Start the discussion